Capsaicin 8% patch Qutenza and other current treatments for neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN)

被引:22
作者
Privitera, Rosario [1 ]
Anand, Praveen [1 ]
机构
[1] Hammersmith Hosp, Imperial Coll London, Div Neurol, London, England
关键词
Capsaicin 8% patch; chemotherapy-induced peripheral neuropathy; neuropathic pain; OXALIPLATIN-INDUCED NEUROPATHY; QUALITY-OF-LIFE; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; TOPICAL CAPSAICIN; PHASE-III; CANCER-PATIENTS; RECEPTOR TRPV1; OPEN-LABEL; CISPLATIN NEUROPATHY;
D O I
10.1097/SPC.0000000000000545
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose of review Current oral treatments for neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) have limited clinical efficacy, and undesirable side-effects. Topically delivered treatments have the advantage of avoiding CNS side-effects, while relieving pain. We have reviewed treatments of neuropathic pain associated with CIPN, focusing on the Capsaicin 8% patch, which can provide pain relief for up to 3 months or longer after a single 30-60-min application. Recent findings Capsaicin 8% patch is a licensed treatment in the EU/UK for neuropathic pain and shown to be safe and effective in providing pain relief for patients with CIPN. Repeated daily oral or topical administrations are not required, as with other current treatments. The side-effects are transient and restricted to the time around patch application. New evidence suggests the Capsaicin 8% patch can promote the regeneration and restoration of skin nerve fibres in CIPN, in addition to the pain relief. The Capsaicin 8% patch is now often a preferred a treatment option for localised neuropathic pain conditions, including the feet and hands in patients with CIPN. Capsaicin 8% patch can be repeated three-monthly, if needed, for a year. In addition to pain relief, it may have a disease-modifying effect.
引用
收藏
页码:125 / 131
页数:7
相关论文
共 108 条
[1]   Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial [J].
Aghili, Mahdi ;
Zare, Mahkameh ;
Mousavi, Nima ;
Ghalehtaki, Reza ;
Sotoudeh, Sarvazad ;
Kalaghchi, Bita ;
Akrami, Shahram ;
Esmati, Ebrahim .
BREAST JOURNAL, 2019, 25 (02) :226-231
[2]   Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain [J].
Akbar, Ayesha ;
Yiangou, Yiangos ;
Facer, Paul ;
Brydon, W. G. ;
Walters, Julian R. F. ;
Anand, Praveen ;
Ghosh, Subrata .
GUT, 2010, 59 (06) :767-774
[3]   Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch [J].
Anand, P. ;
Bley, K. .
BRITISH JOURNAL OF ANAESTHESIA, 2011, 107 (04) :490-502
[4]   Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key [J].
Anand, P .
GUT, 2003, 52 (09) :1233-1235
[5]   The role of endogenous nerve growth factor in human diabetic neuropathy [J].
Anand, P ;
Terenghi, G ;
Warner, G ;
Kopelman, P ;
WilliamsChestnut, RE ;
Sinicropi, DV .
NATURE MEDICINE, 1996, 2 (06) :703-707
[6]   Novel insights on the management of pain: highlights from the 'Science of Relief' meeting [J].
Anand, Praveen ;
Dickenson, Anthony ;
Finco, Gabriele ;
Marinangeli, Franco ;
Polati, Enrico ;
Romualdi, Patrizia ;
Tzschentke, Thomas M. ;
Canonico, Pier Luigi .
PAIN MANAGEMENT, 2019, 9 (06) :521-533
[7]   Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification [J].
Anand, Praveen ;
Elsafa, Enas ;
Privitera, Rosario ;
Naidoo, Kalnisha ;
Yiangou, Yiangos ;
Donatien, Philippe ;
Gabra, Hani ;
Wasan, Harpreet ;
Kenny, Laura ;
Rahemtulla, Amin ;
Misra, Peter .
JOURNAL OF PAIN RESEARCH, 2019, 12 :2039-2052
[8]   Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin [J].
Apostolidis, A ;
Brady, CM ;
Yiangou, Y ;
Davis, J ;
Fowler, CJ ;
Anand, P .
UROLOGY, 2005, 65 (02) :400-405
[9]   Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy [J].
Argyriou, A. A. ;
Polychronopoulos, P. ;
Koutras, A. ;
Xiros, N. ;
Petsas, T. ;
Argyriou, K. ;
Kalofonos, H. P. ;
Chroni, E. .
EUROPEAN JOURNAL OF CANCER CARE, 2007, 16 (03) :231-237
[10]   Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study [J].
Attal, N. ;
Bouhassira, D. ;
Gautron, M. ;
Vaillant, J. N. ;
Mitry, E. ;
Lepere, C. ;
Rougier, P. ;
Guirimand, F. .
PAIN, 2009, 144 (03) :245-252